Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index adding 2.3% and the State Street Healthcare Select Sector SPDR ETF (XLV) climbing 2.2%.
The iShares Biotechnology ETF (IBB) increased 1.4%.
In corporate news, Alkermes (ALKS) shares jumped 5% after it said Tuesday a late-stage trial evaluating its investigational Lumryz oral suspension in adults with idiopathic hypersomnia, a rare condition in which patients require excessive sleep, met all primary and key secondary endpoints.